AbbVie to buys Apogee in $10.9 billion deal
AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.
MOGU (NYSE:MOGU) posted an 11.2% decline in fiscal year 2026 total revenues to RMB125.4 million due to heightened competition.
BioArctic partnered with Eli Lilly (NYSE:LLY) on a neurodegeneration drug deal potentially worth $770 million.
LAB (CRYPTO:LAB) climbed 27.96% to US$15.48 over the past 24 hours, outperforming Bitcoin (CRYPTO:BTC), which gained 0.97%, as buyers defended a key support zone near US$12.
Franklin Templeton has filed plans with the US Securities and Exchange Commission for two exchange-traded funds that combine US equities with Bitcoin (CRYPTO:BTC) exposure through dividend reinvestment.
The Independent Community Bankers of America has asked the Federal Reserve Bank of Kansas City to reassess Kraken Financial's limited-purpose Federal Reserve account.
The price of Brent crude rose by more than US$1 to US$81.66 a barrel following the conclusion of diplomatic talks between the United States and Iran in Switzerland.
Bitcoin (CRYPTO:BTC) is showing signs of weak institutional demand as the Coinbase Premium Index recorded 44 consecutive days in negative territory.
HighCom (ASX:HCL) has updated its market guidance, now forecasting a second-half earnings loss of between $1.2 million and $1.6 million.
MSUSD, a stablecoin issued by MainStreet Finance, fell as much as 85% below its intended US$1 peg after concerns emerged over the protocol's proof-of-reserves infrastructure and market liquidity.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy